Index of ME/CFS Published Research

An A-Z index of the most important published research

31st December 2018

The ME Association
Forward

Welcome to the ME Association Index of Published ME/CFS Research.

This is an A-Z index of the most important published research studies and selected key documents and articles, listed by subject matter, on myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS). It is correct to 31st December 2018.

The Index will be updated at the end of each month and made available in the research section of the ME Association website. Each update will be accompanied by a website blog of that month’s published research abstracts to help keep you informed of the latest research developments.

The Index adopts the subject headings used in the ME Association’s authoritative clinical and research guide which provides a thorough and fully updated review of current clinical knowledge and research evidence.

The guide is written by Dr Charles Shepherd, Hon. Medical Adviser to the ME Association and Dr Abhijit Chaudhuri, consultant neurologist at Queen’s Hospital in Romford.

A new 2018 edition can be ordered from our website shop and is priced at £8.00 for UK residents. We are also pleased to be able to offer free copies of this booklet to health professionals.

The ME Association are very grateful to Dr Barbara de Barros, Charlotte Stephens and Russell Fleming, for producing this Index which is proving a very popular and helpful resource.

Please note: Research published after April 2018 (the date of the latest update to our clinical and research guide) is highlighted in purple in the listing below.
Contents
Forward .................................................................................................................................................. 1
1. Nomenclature and definition ........................................................................................................ 4
2. Epidemiology ...................................................................................................................................... 6
3. Co-morbidity ......................................................................................................................................... 7
4. Biomedical Research ........................................................................................................................ 9
   4.1 Biobank UK ME/CFS................................................................................................................... 9
   4.2 Biomarker Landscape Project ....................................................................................................... 9
   4.3 Cardiac Function .......................................................................................................................... 9
   4.4 Exercise physiology/testing ......................................................................................................... 10
   4.5 Gastrointestinal and microbiome ............................................................................................... 11
   4.6 Gene expression .......................................................................................................................... 12
   4.7 General reviews .......................................................................................................................... 14
   4.8 Genetic predisposition .................................................................................................................. 14
   4.9 Immunology .................................................................................................................................. 15
   4.10 Infection ......................................................................................................................................... 20
   4.11 Ion channels .................................................................................................................................. 24
   4.12 Metabolomics ................................................................................................................................ 24
   4.13 Miscellaneous .............................................................................................................................. 25
   4.14 Mitochondria and energy production ........................................................................................... 25
   4.15 Muscle .......................................................................................................................................... 27
   4.16 Neurology: Autonomic nervous system (ANS) dysfunction ..................................................... 28
   4.17 Neurology: Central nervous system and neuroimaging ............................................................. 29
   4.18 Neurology: Hypothalamic and neuroendocrine function ........................................................... 34
   4.19 Neurology: Neuropsychology and cognitive function ............................................................... 36
   4.20 Neurology: Neurotransmitter function ......................................................................................... 37
   4.21 Pain .............................................................................................................................................. 38
   4.22 Phenotypes and sub-groups ........................................................................................................ 38
   4.23 Post-Exertional Malaise (PEM) .................................................................................................. 39
   4.24 Post-mortem research .................................................................................................................. 40
   4.25 Sleep disturbance ........................................................................................................................ 40
   4.26 Vision ............................................................................................................................................ 42
5. Psychiatry and psychology .............................................................................................................. 43
6. Sociology .................................................................................................................................45
7. Recommendations, challenges and ideas for future research into ME/CFS.............................46
8. Clinical assessment, symptoms and diagnosis ........................................................................47
   8.1 General ..................................................................................................................................47
   8.2 Investigations ..........................................................................................................................50
   8.3 Physical examination ..............................................................................................................53
   8.4 Symptoms .................................................................................................................................53
9. Management ..............................................................................................................................54
   9.1 Cognitive Behavioural Therapy (CBT) .....................................................................................54
   9.2 Complementary and alternative therapies .............................................................................56
   9.3 Diet and nutrition ....................................................................................................................57
   9.4 Exercise, Pacing and activity management .............................................................................58
   9.5 General management .............................................................................................................60
   9.6 PACE Trial, The ....................................................................................................................63
   9.7 Pharmacological treatment .....................................................................................................65
   9.8 Pregnancy ...............................................................................................................................74
10. Prognosis and quality of life .....................................................................................................75
    10.1 Age ........................................................................................................................................75
    10.2 Mortality ...............................................................................................................................75
    10.3 Prognosis and recovery .........................................................................................................75
    10.4 Quality of life .......................................................................................................................76
    10.5 Severe ME ............................................................................................................................77
11. Vaccinations ............................................................................................................................78
12. Children and adolescents ........................................................................................................80
13. Government Documents .........................................................................................................85
    13.1 Disability support .................................................................................................................85
    13.2 Economic cost to the UK .....................................................................................................85
    13.3 General reports, debates and statements .............................................................................86
14. Healthcare ..................................................................................................................................87
Please show your support for the ME Association ........................................................................87
1. Nomenclature and definition


2. Epidemiology


3. Co-morbidity


4. Biomedical Research

4.1 Biobank UK ME/CFS


4.2 Biomarker Landscape Project


4.3 Cardiac Function


4.4 Exercise physiology/testing


4.5 Gastrointestinal and microbiome


Simeonova D, et al. (2018) Recognizing the leaky gut as a trans-diagnostic target for neuroimmune disorders using clinical chemistry and molecular immunology assays, Current Topics in Medicinal Chemistry [Epub ahead of print]. Link: https://www.ncbi.nlm.nih.gov/pubmed/30430944?fbclid=IwAR0tKf959kCWxYJizBj5GD0oW0UsP3OvVD8p1vj58OPwE887K3K3ewBths


4.6 Gene expression


4.7 General reviews


Maxmen A. (2018) A reboot for chronic fatigue syndrome research. *Nature* 553 (7686): 14-17. Link: [https://www.nature.com/articles/d41586-017-08965-0](https://www.nature.com/articles/d41586-017-08965-0)


4.8 Genetic predisposition


4.9 Immunology


4.10 Infection


The ME Association
7 Apollo Office Court, Radcliffe Road, Gawcott, Bucks, MK18 4DF
Registered charity number 801279


4.11 Ion channels


4.12 Metabolomics


Tomas C et al. (2017) Cellular Bioenergetics is Impaired in patients with Chronic Fatigue Syndrome. *PLoS ONE* 12(10). Link: [https://doi.org/10.1371/journal.pone.0186802](https://doi.org/10.1371/journal.pone.0186802)


Yamano E, et al. (2016) Index markers of chronic fatigue syndrome with dysfunction of TCA and urea cycles. *Science Reports* doi: 10.1038/srep34990. Link: [https://www.nature.com/articles/srep34990](https://www.nature.com/articles/srep34990)

**4.13 Miscellaneous**


Saha AK, et al. (2018) Erythrocyte Deformability as a Potential Biomarker for Chronic Fatigue Syndrome, *Blood* [Epub ahead of print] Link: [http://www.bloodjournal.org/content/132/Suppl_1/4874?fbclid=IwAR1CP2Mp6qqDWu12HNG2yBgUbFJUq8MFsXisuRwC_PCugicWhXvnDVpTgzl&sso-checked=true](http://www.bloodjournal.org/content/132/Suppl_1/4874?fbclid=IwAR1CP2Mp6qqDWu12HNG2yBgUbFJUq8MFsXisuRwC_PCugicWhXvnDVpTgzl&sso-checked=true)


**4.14 Mitochondria and energy production**


4.15 Muscle


4.16 Neurology: Autonomic nervous system (ANS) dysfunction


4.17 Neurology: Central nervous system and neuroimaging


4.18 Neurology: Hypothalamic and neuroendocrine function


4.19 Neurology: Neuropsychology and cognitive function


4.20 Neurology: Neurotransmitter function


4.21 Pain


4.22 Phenotypes and sub-groups


4.23 Post-Exertional Malaise (PEM)


4.24 Post-mortem research


4.25 Sleep disturbance


4.26 Vision

5. Psychiatry and psychology


6. Sociology


7. Recommendations, challenges and ideas for future research into ME/CFS


8. Clinical assessment, symptoms and diagnosis

8.1 General


8.2 Investigations


The ME Association 7 Apollo Office Court, Radcliffe Road, Gawcott, Bucks, MK18 4DF
Registered charity number 801279


8.3 Physical examination


8.4 Symptoms

Pain – see Biomedical Research, 4.21 above.
Post-Exertional Malaise – see Biomedical Research, 4.23 above.
Sleep disturbance – see Biomedical Research, 4.26 above.
Vision – see Biomedical Research, 4.28 above.
9. Management

9.1 Cognitive Behavioural Therapy (CBT)


9.2 Complementary and alternative therapies


9.3 Diet and nutrition


The ME Association 7 Apollo Office Court, Radcliffe Road, Gawcott, Bucks, MK18 4DF
Registered charity number 801279

Page 57 | 87


9.4 Exercise, Pacing and activity management


9.5 General management


BACME. (2015) British Association for CFS/ME: Therapy and Symptom Management in CFS/ME. Link: [https://www.bacme.info/](https://www.bacme.info/)


9.6 PACE Trial, The


Shepherd CB. (2016) Patient reaction to the PACE trial [Correspondence]. *The Lancet Psychiatry* 3(2): e7-e8. Link: [http://www.thelancet.com/pdfs/journals/lanpsy/PII%22215-0366%2815%2900546-5.pdf](http://www.thelancet.com/pdfs/journals/lanpsy/PII%22215-0366%2815%2900546-5.pdf)


Vink M. PACE trial authors continue to ignore their own null effect. *Journal of Health Psychology* 22 (9): 1134-1140. Link: https://www.ncbi.nlm.nih.gov/pubmed/28805519


9.7 Pharmacological treatment


9.8 Pregnancy

10. Prognosis and quality of life

10.1 Age


10.2 Mortality


10.3 Prognosis and recovery


10.4 Quality of life


10.5 Severe ME


11. Vaccinations


12. Children and adolescents


Collin SM, et al. (2015) Chronic fatigue syndrome (CFS) or myalgic encephalomyelitis (ME) is different in children compared to in adults: a study of UK and Dutch clinical cohorts. BMJ Open 5(10): e008830. Link: http://bmjopen.bmj.com/content/5/10/e008830


Crawley E and Sterne JAC. (2009) Association between school absence and physical function in paediatric chronic fatigue syndrome/myalgic encephalopathy. Archives of Disease in Childhood 94(10): 752-756. Link: http://adc.bmj.com/content/94/10/752.info


Norris T et al. (2017) Natural course of chronic fatigue syndrome/myalgic encephalomyelitis in adolescents. *Archive of Diseases in Childhood* doi: 10.1136/archdischild-2016-311198. Link: http://adc.bmj.com/content/early/2017/01/19/archdischild-2016-311198


13. Government Documents

13.1 Disability support


13.2 Economic cost to the UK


13.3 General reports, debates and statements


**House of Commons.** (2013) Debate. 11 February col. 517W. Secretary of State re: ME/CFS WHO classification. Link: [https://publications.parliament.uk/pa/cm201213/cmhansrd/cm130211/text/130211w0003.htm#13021150000045](https://publications.parliament.uk/pa/cm201213/cmhansrd/cm130211/text/130211w0003.htm#13021150000045)

**House of Commons.** (2013) Written evidence to Health Select Committee from the ME Association. Link: [https://publications.parliament.uk/pa/cm201415/cmselect/cmhealth/401/401vw11.htm](https://publications.parliament.uk/pa/cm201415/cmselect/cmhealth/401/401vw11.htm)


14. Healthcare


Please show your support for the ME Association

Donate, whatever you can afford, to help us continue with our work and make the UK a better place for people with M.E. Just click the button below:

[Donate now!]

Or why not join the ME Association as a member and become part of our community?

For an annual payment you will not only be helping to keep us doing what we do best, but you will receive ME Essential magazine – with exclusive content – delivered straight to your door.

And, if you join by annual standing order, you can select £10 of free leaflets from the most extensive range available on the internet.